Abstract

BackgroundTacrolimus, the basic component of immunosuppressive therapy to prevent allograft rejection after kidney transplantation, is characterised by great inter/intraindividual variability in its pharmacokinetics, partly explained by polymorphisms in metabolising enzymes.PurposeTo...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call